Printer Friendly

JOHNSON & JOHNSON COMMENTS ON FDA ADVISORY PANEL RECOMMENDATION ON ACETAMINOPHEN AND ALCOHOL

 NEW BRUNSWICK, N.J., June 29 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today commented on a recommendation by the U.S. Food and Drug Administration Over-the-Counter Drug Advisory Committee concerning acetaminophen use in alcoholics:
 We agree with the committee's conclusion that acetaminophen/alcohol problems are a very rare effect limited to chronic alcoholics. While we continue to believe that the available scientific data do not warrant a warning for acetaminophen products, we are pleased that the Advisory Committee concluded that any warning should not be implemented until the risk of gastrointestinal bleeding caused by aspirin or ibuprofen when used with alcohol has been addressed.
 We believe it is important to emphasize that this issue has nothing to do with the social drinker. It is meant for the chronic alcoholic -- someone who cannot make it through the day without heavy amounts of alcohol... someone whose ability to function in daily life is impaired. It is this type of person who should consult a physician about appropriate use of pain relievers.
 Yet even among this population group, acetaminophen-related problems with alcohol are extremely rare. They virtually always involve a combination of extremes -- chronic alcohol abuse and acetaminophen overdose. Acetaminophen-related problems among alcoholics are almost non-existent at recommended doses.
 Acetaminophen has established a remarkable safety record from over 30 years of patient use. Our brand of acetaminophen, TYLENOL, is used by over 60 million patients annually. In fact, it is the pain reliever doctors recommend most for alcoholic patients because of its safety record when used as recommended and because other OTC analgesics such as aspirin and even ibuprofen -- at recommended doses -- can cause gastrointestinal disorders such as ulceration and bleeding.
 -0- 6/29/93
 /CONTACT: F.R. Kniffin of Johnson & Johnson, 908-524-3535 or (home) 609-799-0369/
 (JNJ)


CO: Johnson & Johnson ST: New Jersey IN: MTC SU:

TM-MG -- NY092 -- 6936 06/29/93 18:26 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:311
Previous Article:PAINEWEBBER MORTGAGE ACCEPTANCE CORP.'S IV SERIES 1993-5 CLASS A&R RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:JORDAN INDUSTRIES EXTENDS CASH TENDER OFFER
Topics:


Related Articles
BRISTOL-MYERS SQUIBB REPORTS RESULTS
BRISTOL-MYERS SQUIBB REPORTS RESULTS
JOHNSON & JOHNSON STATEMENT REGARDING NEW ENGLAND JOURNAL OF MEDICINE ARTICLE
TYLENOL URGES INDUSTRY TO FOLLOW ITS LEAD ON VOLUNRARY ALCOHOL LABELING
WHITEHALL-ROBINS URGES CONSUMERS TO CONTINUE TO HEED WARNING ABOUT TYLENOL AND ALCOHOL; COMPANY REAFFIRMS VERACITY OF ADVIL AD
FDA Advisory Committee Recommends Approval With Conditions for Cygnus' GlucoWatch(R) Automatic Glucose Monitor.
FDA proposes labeling changes to over-the-counter pain relievers, including potential for liver damage.
Panel backs continued, limited ESA use in selected Oncology patients.
Worse than the cure.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters